Osmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021
Osmotica Pharmaceuticals (Nasdaq: OSMT) will announce its 2021 second quarter financial results on August 16, 2021, after U.S. markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) will announce its 2021 second quarter financial results on August 16, 2021, after U.S. markets close. A conference call led by CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn will follow the announcement at 4:30 p.m. ET. Investors can access the call via toll-free numbers or international lines, and a replay will be available on the company’s website. Osmotica focuses on developing specialty products for underserved markets, operating in both the U.S. and Hungary.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was +6.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial results on Monday, August 16, 2021, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Monday, August 16, 2021 | |
| Time | 4:30 p.m. ET | |
| Toll free (U.S.) | (866) 672-5029 | |
| International | (409) 217-8312 | |
| Conference ID | 1278168 | |
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.